US-20260125636-A1 - LIMOSILACTOBACILLUS REUTERI SUBSP. REUTERI LR1349, AND COMPOSITION INCLUDING THE SAME AND USE THEREOF

US20260125636A1US 20260125636 A1US20260125636 A1US 20260125636A1US-20260125636-A1

Abstract

Limosilactobacillus reuteri subsp. reuteri LR1349 is deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 35135 in accordance with the Budapest Treaty. A method for alleviating blue light-induced retinal damage using a composition containing Limosilactobacillus reuteri subsp. reuteri LR1349 is also provided. The composition is a food product or a pharmaceutical composition.

Inventors

Chi-Hao Wu
Han-Yin HSU
Chia-Chia LEE
Jin-Seng LIN

Assignees

SYNBIO TECH INC.

Dates

Publication Date: 20260507
Application Date: 20250804

Claims (5)

1 . A method for alleviating blue light-induced retinal damage, comprising administering to a subject in need thereof a composition containing Limosilactobacillus reuteri subsp. reuteri LR1349, which is deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 35135 in accordance with the Budapest Treaty.
2 . The method as claimed in claim 1 , wherein the composition is a food product.
3 . The method as claimed in claim 1 , wherein the composition is a pharmaceutical composition.
4 . The method as claimed in claim 3 , wherein the pharmaceutical composition further contains a pharmaceutically acceptable carrier.
5 . The method as claimed in claim 3 , wherein the pharmaceutical composition is in a dosage form selected from the group consisting of an oral dosage form and a parenteral dosage form.

Description

CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation application of International Application No. PCT/CN2025/101757, filed on Jun. 18, 2025, which claims priority to U.S. Provisional Patent Application No. 63/716,916, filed on Nov. 6, 2024. The aforesaid applications are incorporated by reference herein in their entirety. SEQUENCE LISTING XML The Sequence Listing submitted concurrently herewith with a file name of “PE-72139-AM-SEQUENCE_LISTING.xml,” a creation date of Jun. 26, 2025, and a size of 13,974 bytes, is part of the specification and is incorporated by reference in its entirety. FIELD The disclosure relates to Limosilactobacillus reuteri subsp. reuteri LR1349, and a method for alleviating blue light-induced retinal damage using the same. BACKGROUND Blue light is a high-energy visible light, and exposure to blue light too frequently may cause a retina of an eye to be damaged (i.e., retinal damage). At present, there is no clinically effective method to alleviate blue light-induced retinal damage. The only way to avoid such damage is to reduce exposure to blue light sources (e.g., computers, communication devices, and consumer electronics), and to consume health supplements that are beneficial to eyes, such as lutein and fish oil. Lactic acid bacteria (LAB) are generally recognized as safe (GRAS), well-known and widely used probiotics, and have been found to have the effects of inhibiting the growth of gastrointestinal pathogens, alleviating lactose intolerance, anti-cancer and lowering blood pressure. There are many types of lactic acid bacteria that can be used as probiotics, such as Lactobacillus (part thereof is also known as Limosilactobacillus), Lactococcus, Pediococcus, Enterococcus, Streptococcus, and Bifidobacterium. In spite of the aforesaid, there is still a need to develop a method that is effective in alleviation of blue light-induced retinal damage. SUMMARY Accordingly, the present disclosure provides a method for alleviating blue light-induced damage, which can alleviate at least one of the drawbacks of the prior art, and which includes administering to a subject in need thereof a composition containing Limosilactobacillus reuteri subsp. reuteri LR1349, which is deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 35135 in accordance with the Budapest Treaty. BRIEF DESCRIPTION OF THE DRAWINGS Other features and advantages of the disclosure will become apparent in the following detailed description of the embodiment(s) with reference to the accompanying drawings. It is noted that various features may not be drawn to scale. FIG. 1 shows genetic fingerprints of a conventional Limosilactobacillus reuteri subsp. reuteri DSM 20016T (Lane 1) and Limosilactobacillus reuteri subsp. reuteri LR1349 (Lane 2) according to the present disclosure, infra, which are respectively obtained by random amplified polymorphic DNA (RAPD) analysis using different 10-mer primers, and in which Lane M represents a DNA ladder marker (100 bp to 3000 bp). FIG. 2 shows the visual acuity threshold of the mice in each group of Example 2 determined at the end of each of the 8th week and the 16th week after starting irradiation with blue light, infra, in which the data of different groups in each of the 8th week and the 16th week are marked with different English letters to indicate statistical differences therebetween. FIG. 3 shows the retinal potential changes of the mice in each group of Example 2 determined at the end of each of the 8th week and the 16th week after starting the irradiation with the blue light, infra, in which the data of different groups for each of the a-wave and the b-wave measured in each of the 8th week and the 16th week are marked with different English letters to indicate statistical differences therebetween. FIG. 4 shows the result of histopathological analysis of the mice in each group of Example 2 determined at the end of the 16th week after starting the irradiation with the blue light, infra, in which “GCL” represents a ganglion cell layer, “INL” represents an inner nuclear layer, “ONL” represents an outer nuclear layer, “IS/OS” represents an inner segment/outer segment layer, and “RPE” represents a retinal pigment epithelium. FIG. 5 shows the average thickness of the ONL of the mice in each group of Example 2 determined at the end of the 16th week after starting the irradiation with the blue light, infra, in which the data of different groups are marked with different English letters, to indicate statistical differences therebetween. FIG. 6 shows the average thickness of the IS/OS of the mice in each group of Example 2 determined at the end of the 16th week after starting the irradiation with the blue light, infra, in which the data of different groups are marked with different English letters to indicate statistical differences therebetween. FIG. 7 shows the number of nuclei in the ONL of the mice in each gro